Affix Labs develops a patented formulation method that dissolves oily, water-insoluble active ingredients into water-based systems and applies a controlled-release layer that extends efficacy to 12 weeks. Its flagship product, Repeltec, is dermatologically tested and contains no neurotoxic compounds. Repeltec has active substance authorisations in Germany, France, Austria, and Norway, and the company is expanding distribution across those markets with the UK and Poland planned next. Affix Labs is launching a white-label B2B offering, "Powered by Affix Labs," to let FMCG companies, hospitality operators, and pest control manufacturers integrate its technology. The company raised €1 million in a funding round led by VP Capital and Oost NL to support its European rollout. Affix Labs is headquartered in Nijmegen, Netherlands.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2026